Every year, millions of people worldwide suffer a heart attack. Thanks to advances in emergency treatment, many now survive an event that would once have been fatal. But surviving a heart attack isn’t necessarily the end of the story. The damage can be permanent, which increases the risk of heart failure, breathing and a worse quality of life.
Researchers have developed an experimental treatment that could change the way we approach recovery after a heart attack. Rather than simply protecting the remaining heart muscle, the new approach aims to encourage the heart to repair itself. So far it has only been tested in mice.
The results, published in the journal Nature Cardiovascular Research, describe how modified messenger RNA (mRNA) can encourage heart muscle cells to multiply, improving the heart’s ability to pump blood.
Although this is still early-stage research, the study offers the tantalizing possibility that we may one day be able to encourage the adult human heart to regenerate damaged muscle.
Why the heart struggles to repair itself
A heart attack (myocardial infarction) occurs when blood flow through a coronary artery is significantly reduced or even completely blocked. Without oxygen, the cells of the heart muscle begin to die. These specialized cells, called cardiomyocytes, are responsible for the continuous contractions of the heart muscle that pumps blood around the body to our vital organs.
Unlike skin or liver tissue, the adult human heart has limited capacity to replace damaged cells. Instead, dead muscle is largely replaced by fibrous scar tissue. Although this scar helps maintain the structural integrity of the heart, it cannot contract like healthy muscle.
The consequence is a heart that can become progressively weaker, sometimes leading to heart failure.
Modern treatments, such as procedures to reopen blocked arteries, medications and supervised exercise programs, have greatly improved survival. But they cannot replace the heart muscle that has already died.
During the early development of the heart, the cardiomyocytes divide, allowing the heart muscle to grow. Shortly after birth, most mammalian cardiomyocytes largely lose this ability. The researchers investigated whether they could restart this process by making the heart muscle cells produce two proteins called Myc and Cyclin T1.
Myc switches on genes involved in cell growth and division, while cyclin T1 helps activate the machinery cells need to multiply. Together, the proteins can encourage mature heart muscle cells to divide again.
The researchers used modified mRNA to give heart muscle cells instructions to make the two proteins. This is the same basic technology used in COVID vaccines, which temporarily deliver genetic instructions to cells to make a protein that trains the immune system to recognize the virus.
Importantly, mRNA does not need to modify a cell’s DNA. Instead, there are temporary instructions that are naturally broken. This temporary activity is especially important when stimulating cell growth, because uncontrolled cell growth is the basis of cancer.
What happened in the damaged hearts?
The researchers tested their approach in mice after experimentally induced heart attacks.
The researchers injected the modified mRNA directly into the damaged hearts of mice that had suffered heart attacks. The treatment activates genes involved in cell division, prompting the heart muscle cells to multiply. Crucially, the treated mice also showed improvements in heart function.
After 28 days, the treated mice lost less pumping ability than untreated mice. They also had more heart muscle tissue.
In a longer experiment, improvements in heart function were still evident 12 weeks after treatment.
These findings suggest that temporarily activating the heart’s growth machinery may help regain some of the function lost after injury. However, the treatment did not consistently reduce scar tissue. This suggests that the heart’s improved pumping ability does not necessarily mean that damaged muscle has been completely replaced.
One of the most important findings concerns security. Myc is a powerful regulator of cell growth and is also linked to cancer when its activity becomes uncontrolled.
Activating Myc and Cyclin T1 widely throughout the damaged heart could be dangerous. In one experiment, several mice developed a severe disease or died.
Restricting the activation to a smaller region of the heart muscle around the initial injury produced a much more favorable response. The findings highlight a major challenge: Researchers must find a way to stimulate heart muscle cells to divide without triggering uncontrolled growth elsewhere in the heart.
Encouragingly, no tumors were observed during the reported follow-up of mice receiving localized treatment. However, longer studies will be essential to establish safety.
There are significant obstacles before this approach can be routinely tested in patients. The treatment has not yet been shown to regenerate damaged human hearts. Researchers need to figure out how to deliver the treatment safely, find the right dose and monitor for complications such as abnormal heart rhythms and uncontrolled cell growth. Nevertheless, the results represent an important advance in regenerative cardiovascular medicine.
For decades, the focus after a heart attack has been on preventing further damage and helping the surviving heart muscle work more efficiently. This research points to another ambition: to replace some of the muscles that have already been lost.
If future studies show that the approach is both safe and effective in humans, treating a heart attack could one day not only restore blood flow, but also give the heart the instructions it needs to repair itself.